Jim Simons Biotechnology

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
PGEN Precigen, Inc.	$246M	$1.52 Million 0.0% of portfolio	1,600,190	Q3 2024 Added 35.3%
TRDA Entrada Therapeutics, Inc.	$460M	$1.5 Million 0.0% of portfolio	93,800	Q3 2024 Added 110.31%
EYPT Eye Point Pharmaceuticals, Inc.	$284M	$1.5 Million 0.0% of portfolio	187,437	Q3 2024 Added 22.67%
DSGN Design Therapeutics, Inc.	$252M	$1.47 Million 0.0% of portfolio	274,000	Q3 2024 Reduced 28.66%
GBIO Generation Bio Co.	$54.9M	$1.47 Million 0.0% of portfolio	594,300	Q3 2024 Reduced 6.62%
THRD Third Harmonic Bio, Inc.	$337M	$1.42 Million 0.0% of portfolio	104,660	Q3 2024 Reduced 5.03%
AVXL Anavex Life Sciences Corp.	$875M	$1.38 Million 0.0% of portfolio	243,800	Q3 2024 Reduced 47.73%
VRDN Viridian Therapeutics, Inc.\De	$726M	$1.36 Million 0.0% of portfolio	59,600	Q3 2024 Reduced 75.93%
RZLT Rezolute, Inc.	$194M	$1.35 Million 0.0% of portfolio	278,300	Q3 2024 Added 54.25%
DAWN Day One Biopharmaceuticals, Inc.	$867M	$1.32 Million 0.0% of portfolio	94,840	Q3 2024 Added 31.47%
SPRO Spero Therapeutics, Inc.	$33.7M	$1.31 Million 0.0% of portfolio	974,653	Q3 2024 Reduced 0.13%
SEER Seer, Inc.	$141M	$1.3 Million 0.0% of portfolio	664,132	Q3 2024 Added 32.11%
FATE Fate Therapeutics Inc	$143M	$1.27 Million 0.0% of portfolio	362,619	Q3 2024 Reduced 33.89%
CMRX Chimerix Inc	$285M	$1.25 Million 0.0% of portfolio	1,339,290	Q3 2024 Reduced 9.7%
CTMX Cytom X Therapeutics, Inc.	$58M	$1.2 Million 0.0% of portfolio	1,015,000	Q3 2024 Reduced 14.2%
REPL Replimune Group, Inc.	$545M	$1.18 Million 0.0% of portfolio	107,736	Q3 2024 Reduced 25.78%
RVNC Revance Therapeutics, Inc.	$212M	$1.18 Million 0.0% of portfolio	459,300	Q3 2024 Reduced 19.7%
VRCA Verrica Pharmaceuticals Inc.	$327M	$1.18 Million 0.0% of portfolio	147,964	Q3 2024 Added 225.02%
GLUE Monte Rosa Therapeutics, Inc.	$266M	$1.16 Million 0.0% of portfolio	218,700	Q3 2024 Reduced 14.14%
CRBU Caribou Biosciences, Inc.	$99.8M	$1.16 Million 0.0% of portfolio	594,200	Q3 2024 Reduced 59.93%
PLRX Pliant Therapeutics, Inc.	$585M	$1.13 Million 0.0% of portfolio	101,200	Q3 2024 Reduced 60.06%
BDTX Black Diamond Therapeutics, Inc.	$70.1M	$1.1 Million 0.0% of portfolio	253,800	Q3 2024 Reduced 3.83%
IGMS Igm Biosciences, Inc.	$60.5M	$1.1 Million 0.0% of portfolio	66,500	Q3 2024 Reduced 38.82%
ELEV Elevation Oncology, Inc.	$16.5M	$1.07 Million 0.0% of portfolio	1,785,982	Q3 2024 New
MGNX Macrogenics Inc	$195M	$1.05 Million 0.0% of portfolio	318,423	Q3 2024 Reduced 34.21%
KPTI Karyopharm Therapeutics Inc.	$57.5M	$1.03 Million 0.0% of portfolio	1,241,407	Q3 2024 Added 64.16%
KZR Kezar Life Sciences, Inc.	$445M	$998,000 0.0% of portfolio	1,297,074	Q3 2024 Added 66.62%
KRON Kronos Bio, Inc.	$54.5M	$979,000 0.0% of portfolio	979,054	Q3 2024 Added 28.13%
PLX Protalix Bio Therapeutics, Inc.	$109M	$975,000 0.0% of portfolio	955,900	Q3 2024 Added 18.8%
PASG Passage Bio, Inc.	$36.5M	$974,000 0.0% of portfolio	1,392,846	Q3 2024 Added 23.75%
AADI Aadi Bioscience, Inc.	$75.7M	$951,000 0.0% of portfolio	461,822	Q3 2024 Added 5.15%
CLSD Clearside Biomedical, Inc.	$59M	$946,000 0.0% of portfolio	744,889	Q3 2024 Added 27.84%
MRSN Mersana Therapeutics, Inc.	$70M	$931,000 0.0% of portfolio	492,719	Q3 2024 Reduced 65.98%
AUTL Autolus Therapeutics PLC	$215M	$910,000 0.0% of portfolio	250,871	Q3 2024 Reduced 78.09%
BCAB Bio Atla, Inc.	$19.2M	$900,000 0.0% of portfolio	511,400	Q3 2024 Reduced 18.24%
LEGN Legend Biotech Corp	$5.63B	$882,000 0.0% of portfolio	18,100	Q3 2024 New
AMLX Amylyx Pharmaceuticals, Inc.	$205M	$880,000 0.0% of portfolio	271,800	Q3 2024 Reduced 66.51%
STTK Shattuck Labs, Inc.	$50.4M	$874,000 0.0% of portfolio	250,600	Q3 2024 Reduced 36.07%
ADPT Adaptive Biotechnologies Corp	$929M	$867,000 0.0% of portfolio	169,400	Q3 2024 Added 11.59%
INZY Inozyme Pharma, Inc.	$80.3M	$861,000 0.0% of portfolio	164,800	Q3 2024 Reduced 12.27%
WVE Wave Life Sciences Ltd.	$1B	$857,000 0.0% of portfolio	104,520	Q3 2024 New
RPHM Reneo Pharmaceuticals, Inc.	$41.1M	$852,000 0.0% of portfolio	501,534	Q3 2024 Added 13.42%
ABEO Abeona Therapeutics Inc.	$32.9M	$848,000 0.0% of portfolio	134,278	Q3 2024 Reduced 73.32%
IPSC Century Therapeutics, Inc.	$58.3M	$834,000 0.0% of portfolio	488,200	Q3 2024 Added 194.98%
BMEA Biomea Fusion, Inc.	$117M	$831,000 0.0% of portfolio	82,300	Q3 2024 Reduced 74.99%
LUMO Lumos Pharma, Inc.	$36.4M	$827,000 0.0% of portfolio	213,814	Q3 2024 Reduced 0.93%
ABOS Acumen Pharmaceuticals, Inc.	$66.8M	$759,000 0.0% of portfolio	306,100	Q3 2024 Reduced 9.46%
TNYA Tenaya Therapeutics, Inc.	$60.4M	$734,000 0.0% of portfolio	380,468	Q3 2024 Added 141.63%
EWTX Edgewise Therapeutics, Inc.	$1.53B	$733,000 0.0% of portfolio	27,465	Q3 2024 New
IKNA Ikena Oncology, Inc.	$56.6M	$693,000 0.0% of portfolio	400,600	Q3 2024 Reduced 15.91%

Shares Options

Jim Simons

Jim Simons is the founder and chairman of Renaissance Technologies, a successful investment firm that uses quantitative approaches to investing. Simons is known for his expertise in mathematical modeling and has a reputation for being a skilled and successful investor. He has generated strong returns for his clients over the long term.

Track Jim Simons's portfolio

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account